Karen Ebsworth

683 total citations
20 papers, 404 citations indexed

About

Karen Ebsworth is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Karen Ebsworth has authored 20 papers receiving a total of 404 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 13 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Karen Ebsworth's work include Chemokine receptors and signaling (8 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Immunotherapy and Immune Responses (4 papers). Karen Ebsworth is often cited by papers focused on Chemokine receptors and signaling (8 papers), Psoriasis: Treatment and Pathogenesis (6 papers) and Immunotherapy and Immune Responses (4 papers). Karen Ebsworth collaborates with scholars based in United States, United Kingdom and Australia. Karen Ebsworth's co-authors include Thomas J. Schall, Matthew J. Walters, Linda Ertl, Miriam Griffin, Juan C. Jaén, Malcolm N. Palfreyman, Jan‐Anders Karlsson, John E. Souness, Kenneth H. Pollock and Robert Berahovich and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Karen Ebsworth

19 papers receiving 382 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Ebsworth United States 9 203 157 138 55 51 20 404
Taher E. Taher United Kingdom 15 405 2.0× 92 0.6× 123 0.9× 52 0.9× 31 0.6× 23 669
Yoshikazu Kuboi Japan 12 125 0.6× 100 0.6× 84 0.6× 34 0.6× 13 0.3× 23 325
Namratha Sheshadri United States 8 81 0.4× 94 0.6× 159 1.2× 99 1.8× 28 0.5× 10 395
Glenn Whiteside New Zealand 7 153 0.8× 199 1.3× 121 0.9× 13 0.2× 19 0.4× 7 389
Eider Egilegor Spain 5 143 0.7× 150 1.0× 219 1.6× 51 0.9× 18 0.4× 5 422
Jiunn-Chang Lin Taiwan 11 124 0.6× 152 1.0× 150 1.1× 60 1.1× 16 0.3× 27 426
Xinfeng Yan China 11 179 0.9× 83 0.5× 177 1.3× 21 0.4× 15 0.3× 17 483
Hester Franks United Kingdom 11 260 1.3× 219 1.4× 84 0.6× 27 0.5× 8 0.2× 19 421
David S.L. Kim United States 7 144 0.7× 118 0.8× 238 1.7× 21 0.4× 14 0.3× 8 406
Touko Inao Japan 12 145 0.7× 280 1.8× 184 1.3× 28 0.5× 21 0.4× 20 495

Countries citing papers authored by Karen Ebsworth

Since Specialization
Citations

This map shows the geographic impact of Karen Ebsworth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Ebsworth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Ebsworth more than expected).

Fields of papers citing papers by Karen Ebsworth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Ebsworth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Ebsworth. The network helps show where Karen Ebsworth may publish in the future.

Co-authorship network of co-authors of Karen Ebsworth

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Ebsworth. A scholar is included among the top collaborators of Karen Ebsworth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Ebsworth. Karen Ebsworth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sullivan, Kathleen M., Linda Ertl, Zhenhua Miao, et al.. (2022). 499 The small molecule PD-L1 inhibitor CCX559 preferentially accumulates in tumors, resulting in depletion of cell-surface PD-L1 in a murine preclinical model. Regular and Young Investigator Award Abstracts. A520–A520. 1 indexed citations
2.
Tapia, Gonzalo, Joanne Lundy, Gary Richardson, et al.. (2022). Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors.. Journal of Clinical Oncology. 40(16_suppl). 2593–2593. 2 indexed citations
3.
Ebsworth, Karen, James J. Campbell, Linda Ertl, et al.. (2019). 725 Targeting chemokine receptors CCR6 and CXCR2 in a murine model of IL-36α-induced pustular psoriasis.. Journal of Investigative Dermatology. 139(5). S124–S124. 1 indexed citations
4.
Campbell, James J., Karen Ebsworth, Linda Ertl, et al.. (2019). Efficacy of Chemokine Receptor Inhibition in Treating IL-36α–Induced Psoriasiform Inflammation. The Journal of Immunology. 202(6). 1687–1692. 21 indexed citations
5.
Ebsworth, Karen, et al.. (2018). 1058 IL36-mediated skin inflammation requires signaling through chemokine receptor CCR6. Journal of Investigative Dermatology. 138(5). S179–S179. 1 indexed citations
6.
Parker, Richard, Chris J. Weston, Zhenhua Miao, et al.. (2018). CC chemokine receptor 2 promotes recruitment of myeloid cells associated with insulin resistance in nonalcoholic fatty liver disease. American Journal of Physiology-Gastrointestinal and Liver Physiology. 314(4). G483–G493. 47 indexed citations
7.
Campbell, James J., Karen Ebsworth, Linda Ertl, et al.. (2018). IL36-Mediated Skin Inflammation Requires Signaling Through Chemokine Receptor CCR6.. The Journal of Immunology. 200(Supplement_1). 176.19–176.19. 1 indexed citations
8.
Campbell, James J., et al.. (2017). 669 Chemokine receptor CCR6 antagonist reverses psoriaform dermatitis by preventing accumulation of γδT17 cells in skin. Journal of Investigative Dermatology. 137(5). S115–S115. 1 indexed citations
9.
Campbell, James J., Karen Ebsworth, Linda Ertl, et al.. (2017). IL-17–Secreting γδ T Cells Are Completely Dependent upon CCR6 for Homing to Inflamed Skin. The Journal of Immunology. 199(9). 3129–3136. 42 indexed citations
10.
Ebsworth, Karen, et al.. (2016). 521 Chemokine receptor inhibition as a novel therapeutic approach for psoriasis. Journal of Investigative Dermatology. 136(5). S92–S92. 1 indexed citations
11.
Bekker, Pirow, Karen Ebsworth, Matthew J. Walters, et al.. (2015). CCR9 Antagonists in the Treatment of Ulcerative Colitis. Mediators of Inflammation. 2015(1). 628340–628340. 18 indexed citations
12.
Jung, Heiyoun, A. Bischof, Karen Ebsworth, et al.. (2015). Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer. Journal for ImmunoTherapy of Cancer. 3(S2). 15 indexed citations
13.
Parker, Richard, Matthew J. Walters, Linda Ertl, et al.. (2014). Therapeutic use of a clinical stage CCR2 inhibitor, CCX872, in obesity-associated steatohepatitis. The Lancet. 383. S78–S78. 8 indexed citations
14.
Walters, Matthew J., Karen Ebsworth, Timothy J. Sullivan, et al.. (2013). CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens. Immunology Letters. 151(1-2). 44–47. 5 indexed citations
15.
Berahovich, Robert, Brian A. Zabel, Susanna Lewén, et al.. (2013). Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels. Immunology. 141(1). 111–122. 78 indexed citations
16.
Ebsworth, Karen, Matthew J. Walters, Linda Ertl, et al.. (2012). The effect of the CXCR7 inhibitor CCX662 on survival in the ENU rat model of glioblastoma.. Journal of Clinical Oncology. 30(15_suppl). e13580–e13580. 1 indexed citations
17.
Du, Xiaohui, Darin J. Gustin, Xiaoqi Chen, et al.. (2009). Imidazo-pyrazine derivatives as potent CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 19(17). 5200–5204. 29 indexed citations
18.
Walters, Matthew J., Robert Berahovich, Linda Ertl, et al.. (2009). CCR9 Inhibition in the treatment of Colonic Inflammation. Inflammatory Bowel Diseases. 15. S47–S47. 2 indexed citations
19.
Du, Xiaohui, Xiaoqi Chen, Jason Duquette, et al.. (2007). Design and optimization of imidazole derivatives as potent CXCR3 antagonists. Bioorganic & Medicinal Chemistry Letters. 18(2). 608–613. 26 indexed citations
20.
Souness, John E., Miriam Griffin, Karen Ebsworth, et al.. (1996). Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNFα generation from human monocytes by interacting with a ‘low‐affinity’ phosphodiesterase 4 conformer. British Journal of Pharmacology. 118(3). 649–658. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taher E. Taher Breakdown of academic impact, for papers by Yoshikazu Kuboi Breakdown of academic impact, for papers by Namratha Sheshadri Breakdown of academic impact, for papers by Glenn Whiteside Breakdown of academic impact, for papers by Eider Egilegor Breakdown of academic impact, for papers by Jiunn-Chang Lin Breakdown of academic impact, for papers by Xinfeng Yan Breakdown of academic impact, for papers by Hester Franks Breakdown of academic impact, for papers by David S.L. Kim Breakdown of academic impact, for papers by Touko Inao
Rankless by CCL
2026